Since CMV infections may be serious and even fatal for certain high-risk patients (e.g. transplant recipients, AIDS patients, premature newborns), transfusions with CMV-negative cellular blood derivatives are still essential. Consequently, the need for anti-CMV screening assays is increasing.

Vironostika anti-CMV III is part of a range of easy-to-automate blood bank screening assays.

Vironostika anti-CMV III
192 tests (24(2x4))